An Integrated Platform from Target to Evidence.
ImageNova Bioscience connects AI-driven target discovery, probe synthesis, radiolabeling, in vitro evaluation, tumor models, and in vivo molecular imaging to generate translational evidence for precision oncology and radiopharmaceutical development.
Drug development fails when biology stays invisible.
Many therapeutic candidates advance with incomplete understanding of target expression, biodistribution, pharmacokinetics, target engagement, and in vivo response. ImageNova helps make these biological signals visible earlier.
From molecular hypothesis to in vivo evidence.
Target Discovery
Bio-Ligand Design
Probe Synthesis & Radiolabeling
In Vitro Evaluation
Tumor Models
Molecular Imaging Validation
STEP 01
STEP 02
STEP 03
STEP 04
STEP 05
STEP 06
Translational Decision
STEP 07
Platform Pillars
AI-Driven Target Discovery
Leveraging high-dimensional datasets to identify disease-relevant targets with high translational potential, specifically focusing on expression patterns suitable for radioligand therapy.
Probe Synthesis & Radiolabeling
Precision engineering of novel bio-ligands and radio-conjugates. We optimize PK/PD profiles earlier to ensure high target uptake and minimal off-target biodistribution.
In Vivo Molecular Imaging
Quantitative evaluation across multiple tumor models. Our non-invasive PET/CT imaging provides real-time validation of target engagement and therapeutic response.
Translational Decision Support
Bridging the gap from bench to first-in-human. We provide investor-ready translational evidence and clinical validation data to support Go/No-Go development decisions.
Designed to support better development decisions.
Our platform helps biotech and pharma teams evaluate target biology, candidate distribution, tumor uptake, PK/PD, target engagement, therapeutic response, and translational potential.